Global Information
회사소개 | 문의 | 비교리스트

호산구성 식도염 : 파이프라인 리뷰

Eosinophilic Esophagitis - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 246006
페이지 정보 영문 131 Pages
가격
US $ 2,000 ₩ 2,396,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,792,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,189,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


호산구성 식도염 : 파이프라인 리뷰 Eosinophilic Esophagitis - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 131 Pages

호산구성 식도염이란 음식·알레르겐·탄산 등에 반응하여 호산구(백혈구의 일종)가 식도 조직 내부에 축적되는 증상입니다. 주요 증상으로 체중 감소나 복통, 구역질·구토, 기침, 가슴 답답함 및 통증 등이 있습니다. 질병 소질에는 HIV/AIDS 감염에 따른 면역계 약체화, 당뇨병, 백혈병, 림프종, 기타 자가면역질환, 화학치료, 아스피린제·항염증제, 만성 구토, 비만, 음주, 흡연 등이 있습니다. 주요 치료법에는 항바이러스제, 항진균제, 진통제 등이 있습니다.

세계 각국에서의 호산구성 식도염(Eosinophilic Esophagitis) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발·출시의 최신 동향, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

목차

서론

  • 분석 범위

호산구성 식도염 개요

치료제 개발

  • 호산구성 식도염용 파이프라인 제품 : 개요
  • 각 기업에서 개발중인 호산구성 식도염 치료제
  • 호산구성 식도염 치료제 : 개발중인 제품 리스트(기업별)

호산구성 식도염 : 치료제 평가

  • 표적별
  • 작용기서별
  • 투여 방법별
  • 분자 종류별

호산구성 식도염 치료제 개발에 참여하고 있는 기업

  • Adare Pharmaceuticals Inc
  • Calypso Biotech SA
  • Celgene Corp
  • DBV Technologies SA
  • Dr. Falk Pharma GmbH
  • Quorum Innovations LLC
  • Regeneron Pharmaceuticals Inc
  • Shire Plc

약제 개요

호산구성 식도염 치료제 : 개발이 휴지 상태인 제품

호산구성 식도염 관련 제품 개발 마일스톤

  • 주목해야 할 최신 동향과 프레스 릴리스

부록

도표

KSM 17.05.19

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Eosinophilic Esophagitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Eosinophilic Esophagitis - Pipeline by Adare Pharmaceuticals Inc, H1 2020
  • Eosinophilic Esophagitis - Pipeline by Allakos Inc, H1 2020
  • Eosinophilic Esophagitis - Pipeline by Arena Pharmaceuticals Inc, H1 2020
  • Eosinophilic Esophagitis - Pipeline by Banner Life Sciences LLC, H1 2020
  • Eosinophilic Esophagitis - Pipeline by Bristol-Myers Squibb Co, H1 2020
  • Eosinophilic Esophagitis - Pipeline by Calypso Biotech SA, H1 2020
  • Eosinophilic Esophagitis - Pipeline by DBV Technologies SA, H1 2020
  • Eosinophilic Esophagitis - Pipeline by Dr. Falk Pharma GmbH, H1 2020
  • Eosinophilic Esophagitis - Pipeline by EsoCap AG, H1 2020
  • Eosinophilic Esophagitis - Pipeline by GlaxoSmithKline Plc, H1 2020
  • Eosinophilic Esophagitis - Pipeline by Humanigen Inc, H1 2020
  • Eosinophilic Esophagitis - Pipeline by Kyowa Kirin Co Ltd, H1 2020
  • Eosinophilic Esophagitis - Pipeline by Morphic Holding Inc, H1 2020
  • Eosinophilic Esophagitis - Pipeline by Quorum Innovations LLC, H1 2020
  • Eosinophilic Esophagitis - Pipeline by RAPT Therapeutics Inc, H1 2020
  • Eosinophilic Esophagitis - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
  • Eosinophilic Esophagitis - Pipeline by Suzhou Connect Biopharmaceuticals Ltd, H1 2020
  • Eosinophilic Esophagitis - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
  • Eosinophilic Esophagitis - Dormant Projects, H1 2020

List of Figures

  • Number of Products under Development for Eosinophilic Esophagitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Eosinophilic Esophagitis - Pipeline Review, H1 2020, provides an overview of the Eosinophilic Esophagitis (Gastrointestinal) pipeline landscape.

Eosinophilic esophagitis is disease characterized by the presence of a large number of a special type of white blood cell, the eosinophil that can cause inflammation in the esophagus. Symptoms include poor weight gain, abdominal pain, nausea, and vomiting, coughing, heartburn and chest pain. Risk factors include weakened immune system, chemotherapy, aspirin and anti-inflammatory medications, chronic vomiting, obesity and alcohol and cigarette use. Treatment includes antiviral, antifungal and pain relievers.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Eosinophilic Esophagitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Eosinophilic Esophagitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Eosinophilic Esophagitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 5, 3, 2 and 10 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Eosinophilic Esophagitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Eosinophilic Esophagitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Eosinophilic Esophagitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Eosinophilic Esophagitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Eosinophilic Esophagitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Eosinophilic Esophagitis - Overview
  • Eosinophilic Esophagitis - Therapeutics Development
  • Eosinophilic Esophagitis - Therapeutics Assessment
  • Eosinophilic Esophagitis - Companies Involved in Therapeutics Development
  • Eosinophilic Esophagitis - Drug Profiles
  • Eosinophilic Esophagitis - Dormant Projects
  • Eosinophilic Esophagitis - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q